← Back to Home

CUR-001 completes transfer to automated CAR-T manufacturing process, with solid tumor human trial expected to begin in 2027

Currus and Octane move cell manufacturing to the closed Cocoon platform to prepare supplies for a first-in-human trial. The companies say manual work and viral vector requirements have decreased, but have not disclosed the extent of the reductions, and efficacy remains to be validated clinically.

By SURL BioNews

Before a cell therapy can enter human trials, it must address not only whether its design can fight tumors, but also whether it can be manufactured consistently for each patient. Currus Biologics and Octane Biotech announced on October 26 that they had transferred the cell manufacturing process for CUR-001, a candidate therapy for solid tumors, to the closed, automated Cocoon platform to prepare supplies for a first-in-human trial expected to begin in early 2027.

According to the companies’ joint announcement and Octane’s account of the same development, products for the Phase 1 trial will be manufactured by Cell Therapies Pty Ltd in Melbourne, Australia, which has completed the technology transfer for the automated process. This development advances manufacturing arrangements toward actual supply; when the first patient will receive treatment remains subject to the company’s anticipated timeline.

The companies said switching to Cocoon reduced both the hands-on time required for the process and the amount of viral vector used per batch. For autologous CAR-T therapies made from patients’ own cells, these two resource requirements affect manufacturing costs. However, the announcement provided no figures on the extent of the reductions, costs, or batch comparisons. The savings from automation therefore cannot currently be quantified, nor can future treatment prices be inferred from them.

CUR-001 combines autologous CAR-T cells targeting mesothelin with a bispecific antibody called BEAT. The former recognizes the tumor target; the latter is designed to engage both CAR-T cells and antigen-presenting cells, with the aim of promoting immune activation in lymphoid tissues to support CAR-T cell function.

This combination seeks to address biological barriers to using CAR-T in solid tumors: the immunosuppressive environment surrounding tumors may limit T-cell expansion, persistence, and entry into tumor tissue. Manufacturing automation helps prepare clinical supplies, but cannot directly answer whether this immune-based design can overcome those limitations in patients.

Currus previously announced that the U.S. Food and Drug Administration (FDA) had allowed the investigational new drug application for CUR-001 to proceed. The planned study is a first-in-human, open-label Phase 1 basket trial that will enroll patients with mesothelin-positive, advanced, refractory solid tumors. This regulatory development means the study can begin; it does not mean the therapy has received marketing approval or that its safety and efficacy have been confirmed.

Next, manufacturing must demonstrate consistency in supplying the trial, while the therapy must generate human safety and preliminary activity data. The results announced so far come primarily from the partner companies’ descriptions of the manufacturing process, with no patient efficacy results yet available. For CUR-001, completing the technology transfer fulfills an important preparation step for entering clinical trials. Whether it can deliver durable antitumor effects remains for the trial to determine.

References

  1. Currus Biologics via GlobeNewswire
  2. Octane Biotech